Dordaviprone is under clinical development by Chimerix and currently in Phase II for Paraganglioma (Glomus Jugulare Tumor). According to GlobalData, Phase II drugs for Paraganglioma (Glomus Jugulare Tumor) have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dordaviprone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dordaviprone overview
ONC-201 is under development for the treatment of high-grade glioma including thalamus, hypothalamus, brainstem, cerebellum, gliosarcoma, midbrain, or spinal cord, diffuse midline glioma, neuroendocrine tumors, diffuse intrinsic pontine glioma, pheochromocytoma-paraganglioma (PC-PG), triple-negative breast cancer and endometrial, colorectal, prostate cancers, , relapsed or refractory acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, multiple myeloma and unspecified indication. The drug candidate is administered orally in the form of capsules. The drug candidate is developed based on cell-based molecular imaging platform. It acts by targeting JAK/STAT pathway, Akt and ERK and ClpP.
It was also under development for the treatment of non-small cell lung cancer. It was also under development for the treatment of relapsed/refractory non-Hodgkin's lymphoma includes diffuse large b-cell lymphoma, mantle cell lymphoma, cutaneous T-cell lymphoma and transformed large cell lymphoma.
Chimerix overview
Chimerix is a biopharmaceutical company. It develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s pipeline product portfolio includes ONC201, ONC206, ONC212, CMX521 drug candidates. Its products are used to treat various diseases like gliomas, central nervous system tumors, SARS-CoV-2 (COVID-19), and IND-enabling studies. Its brincidofovir tablet and oral suspension formulations are used in the treatment of smallpox disease in adult and pediatric patients. The company markets its products under the brand name TEMBEXA. The organization works in partnership with Oncoceutics, Inc., Cantex Pharmaceuticals, BARDA, and SymBio Pharmaceuticals. Chimerix is headquartered in Durham, North Carolina, the US.
For a complete picture of Dordaviprone’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Dordaviprone in Paraganglioma (Glomus Jugulare Tumor)
Premium Insights
The gold standard of business intelligence.
